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ABSTRACT 
Bronchitis refers to the inflammation of the bronchi and bronchioles, which helps in the 
movement of the air through the lungs. Bronchitis can be of two types acute and chronic. 
Acute bronchitis is very common which mainly occurs due to respiratory infections like 
common cold and chronic bronchitis on the other hand occurs due to the constant irritation 
which leads to inflammation of the bronchi mainly due to smoking or environment dust and 
pollution. Major signs and symptoms are dyspnea, cough with sputum. Main risk factors 
involves smoking, environmental pollution, dust and recurrent lung infections. In Ayurveda it 
can be correlated with Tamakashwasa on the basis of similar manifestations. Drug delivery 
mode through nasal route is termed as inhalation therapy; it has various plus points as 
compare oral drug administration mode. There is an immediate effect, drug goes directly to 
the site of pathogenesis and quick abruption of the drug. Rasayana therapy is mainly refers to 
the attainment of the excellence of body fluids, this helps in the rejuvenation of the body and 
reduce the recurrence of the disease, it also helps in improving the strength and immunity of 
the body. A case study was done on bronchitis in the All India Institute of Ayurveda hospital. 
Inhalation therapy was given for 15 days followed by Rasayana therapy for one month. There 
was marked improvement in all the signs and symptoms of the disease along with increase in 
pulmonary function test, also there is no recurrence of the signs and symptoms of the disease 
after the whole course of treatment during follow up. 
KEYWORDS: Bronchitis, Dyspnea, Tamakshwasa, Inhalation therapy, Rasayana therapy. 
INTRODUCTION 
Bronchitis refers to the inflammation of the 
bronchi and bronchioles, which helps in the 
movement of the air through the lungs. Chronic 
bronchitis mainly manifested by cough with mucus 
for more than 3 months for two consecutive years. 
Bronchitis can be of two types acute and chronic. 
Acute bronchitis is very common which mainly 
occurs due to respiratory infections like common 
cold and chronic bronchitis on the other hand occurs 
due to the constant irritation which leads to 
inflammation of the bronchi mainly due to smoking 
or environment dust and pollution.  
Acute bronchitis is common term used for the 
inflammation of the bronchi of lung. The most 
common feature includes cough with sputum along 
with shortness of breath chest discomfort fever on 
and off.  
The major cause of bronchitis is viral 
infection which is in more than 90% of cases. This 
viral infection spread through air or by direct contact. 
Main risk factors for bronchitis include smoking, 
exposure Risk factors include exposure to tobacco 
smoke, dust, and other air pollution. A small number 
of cases are due to high levels of air pollution or 
bacteri. 
Acute bronchitis is one of the most common 
diseases. About 5% of adults are affected and about 
6% of children have at least one episode a year. It 
occurs more often in the winter.  
Chronic bronchitis is defined as a productive 
cough that lasts for three months or more per year 
for at least two years. Most people with chronic 
bronchitis have chronic obstructive pulmonary 
disease (COPD). Protracted bacterial bronchitis is 
defined as a chronic productive cough with a 
positive bronchoalveolar lavage that resolves with 
antibiotics. Symptoms of chronic bronchitis may 
include wheezing and shortness of breath, especially 
upon exertion and low oxygen saturations. The cough 
is often worse soon after awakening and the sputum 
produced may have a yellow or green color and may 
be streaked with specks of blood.  
Most cases of chronic bronchitis are caused 
by smoking cigarettes or other forms of tobacco. 
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Additionally, chronic inhalation of air pollution or 
irritating fumes or dust from hazardous exposures in 
occupations such as coal mining, grain handling, 
textile manufacturing, livestock farming and metal 
moulding may also be a risk factor for the 
development of chronic bronchitis. Protracted 
bacterial bronchitis is usually caused by 
Streptococcus pneumoniae, Non-typable 
Haemophilus influenzae, or Moraxella catarrhalis 
Individuals with an obstructive pulmonary 
disorder such as bronchitis may present with a 
decreased FEV1 and FEV1/FVC ratio on pulmonary 
function tests. Unlike other common obstructive 
disorders such as asthma or emphysema, bronchitis 
rarely causes a high residual volume (the volume of 
air remaining in the lungs after a maximal exhalation 
effort).  
Chronic bronchitis has a 3. 4% to 22% 
prevalence rate among the general population. 
Individuals over the age of 45, smokers, those that 
live in areas with high air pollution and those have 
asthma have a higher risk of developing chronic 
bronchitis. This wide range is due to the different 
definitions of chronic bronchitis which can be defined 
based on signs and symptoms or the clinical 
diagnosis of the disorder. Chronic bronchitis tends to 
affect men more often than women. While the 
primary risk factor for chronic bronchitis is smoking, 
there is still a 4%-22% chance that people with 
chronic bronchitis were never smokers. This might 
suggest other risk factors such as the inhalation of 
fuels, dusts, and fumes. Obesity has also been linked 
to an increased risk in the onset of chronic bronchitis.  
For either acute bronchitis or chronic bronchitis, 
signs and symptoms may include: 
 Cough 
 Production of mucus (sputum), which can be 
clear, white. 
 Fatigue 
 Shortness of breath 
 Slight fever and chills 
 Chest discomfort 
Risk factors 
Factors that increase risk of bronchitis include: 
 Cigarette smoke. People who smoke or who live 
with a smoker are at higher risk of both acute 
bronchitis and chronic bronchitis.  
 Low resistance. This may result from another 
acute illness, such as a cold, or from a chronic 
condition that compromises your immune 
system. Older adults, infants and young children 
have greater vulnerability to infection.  
 Exposure to irritants on the job. Your risk of 
developing bronchitis is greater if you work 
around certain lung irritants, such as grains or 
textiles, or are exposed to chemical fumes.  
 Gastric reflux. Repeated bouts of severe 
heartburn can irritate the throat and leads to 
bronchitis.  
Table 1 
 
Bronchitis can be correlated with 
Tamakshwasa in Ayurveda on the basis of clinical 
signs and symptoms. Due to various causative factors 
there is derangement in Vatadosha and Kaphadosha 
simultaneously, vitiated Vatadosha obstructed by 
vitiated Kapahadosha leads to the abnormal 
movement which results in various manifestation 
like dyspnea and cough and leads to development of 
Tamakshwasa disease. Inhalation therapy is the use 
drug through nasal route to treat respiratory 
diseases and conditions. It is mainly helps in 
improving breathing and lung function in order to 
alleviate the symptoms of chronic respiratory issues, 
such as asthma, bronchitis, chronic obstructive 
pulmonary disease (COPD), and emphysema. This 
therapy may also be used to treat respiratory 
Ahmed Nasreen, KajariaDivya. Evaluating clinical Efficacy of Kantakari Aerosol in the Management of Bronchitis 
     IJAPR | March 2019 | Vol 7 | Issue 3  33 
complications that might result from heart attacks 
and stroke.  
Most common types of inhalation therapy 
include oxygen therapy, mechanical ventilation, 
incentive spirometry, nebulization therapy, and 
continuous positive airway pressure (CPAP). Any 
drug administration done through nasal route come 
under the category of inhalation therapy. In 
Ayurveda this therapy is termed as Nasya therapy 
which is one of Panchkarma procedure mentioned in 
Ayurveda. Acharyacharak has described 5 types of 
Nasya therapy. Inhalation therapy can be correlated 
with Dhumapaan. There are different diseases in 
which Nasya therapy is administered which are 
mentioned in Ayurvedic classics.  
Administration of drug through nasal route is 
well described in Ayurvedic texts for the 
management of Tamaka Shvasa. Different form of 
drugs like Kvatha (decoction), Svarasa (juice), Kalka 
(paste), Taila (oil preparations), Dhumapana 
(smoking of herbs), etc. are instructed to be given 
through nasal route for the management of acute as 
well as chronic exacerbation of dyspnea. Drugs given 
through nasal route helps in relieving cough, easily 
expulsion of sputum and also helps in revitalizing the 
respiratory drive.  
Rasayana therapy is Ayurveda devotes one 
whole branch for studying the methodology for 
prevention of aging, rejuvenation and achieving the 
bliss of ever youthfulness termed as “Rasayana”. 
Regeneration is the process of regrow, restore and 
renewal. It literary means formation of any new thing 
whether a tissue, cell or a complete organ. At its most 
elementary level, regeneration is mediated by the 
molecular processes of gene regeneration. 
Regeneration is different from reproduction. The 
Rasayana term is formed by two words – Rasa and 
Ayana. It refers to the attainment of excellence of 
vital fluids of the body to achieve a state of positive 
health and disease free living. Rasa means the first 
nutritive Dhatu. In Ayurveda, Dhatu refers to 
constitutional unite of the body that support as well 
as nourish the body. On the basis of its morphology 
and physiology it can be correlated "Lymphoid 
plasma” which is believed to be the nutritious fluid 
part of the blood that has escaped from the blood-
vessels, and which has irrigated the tissues and 
ministered to their nutrition. Ayana refers to acquire, 
in the present context it means the method or 
technique or pathways for acquiring best Rasa dhatu. 
Thus Rasayana refers to all the pathways or 
techniques by which vitality and body immunity can 
be enhanced for the promotion and maintenance 
healthy tissues, for the replenishment of daily wear 
and tear and for regeneration of tissues. Here is case 
of Bronchitis which is treated through the Ayurvedic 
inhalation therapy and Rasayana therapy.  
Case Presentation 
A 65 years old male patient (UHID no: 
339776) visited Kayachikitsa OPD of AIIA hospital on 
31 December 2018 with complaints of shortness of 
breath, cough with sputum since one year.  
History of Present illness: According to the patient 
he was asymptomatic before 1 year then gradually he 
developed cough with sputum and breathlessness, 
weakness all over the body. He took allopathic 
treatment for this but could not got satisfactorily 
relief, so he came to All India Institute of Ayurveda 
(AIIA) for his further management.  
History of past illness: no history of HTN/DM/ 
Hypothyroidism/Tuberculosis.  
Examination
Table 2: 
General Physical examination 
 Appetite: average  
 Bowel: irregular Bladder: normal 
Sleep: average 
 Blood pressure:130/70 mmHg 
Pulse:78/min, regular (Vatapittaj) 
 Respiratory rate:16/min 
 Temperature:normalPallor:absentIct
erus:absentLymphadenopathy:none 
 Clubbing: absent  
 Pedal oedema: not present  
 
Dashvidhpariksha 
 Prakriti– Vatapittaja 
 Vikriti–Vataja, Kaphaja 
 Sara – Madhyam 
 Samhana –Madhyam 
 Ahara Shakti – Madhyam 
 Abhyarana Shakti – Madhyam 
 Jarana Shakti – Madyam 
 Vyayam Shakti – Avara 
 Vaya – Vridha 
 Satva – Madhyam 
 Satmya – Madhyam 
 Bala – Avara 
 Ashtavidhapariksha 
Systemic examination 
 Cardio vascular System: 
S1S2normal, no added 
sounds.  
 Respiratory System: 
Expiratory rate= 
inspiratory rate. on 
auscultation wheezing 
sound present.  
 Gastrointestinal System: 
No abnormality detected.  
 Nervous System: Higher 
function-normal  
 Motor functions- normal 
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 Nadi– 78/min (Vatapittaj)  
 Jivha – Sama 
 Mala – Malabaddhata 
 Mutra – Samyaka 
 Shabda – samyaka 
 Sparsha – Samanya 
 Drik – Samanya 
 Akriti – Madhyam 
Samprapti Vighatana 
Dosha - VatajaKaphaja 
Dushya - Ras, Rakta,  
Srotas - Pranavaha, Rasavaha 
Adhisthana - Uraha.  
On the basis of above examination and signs and symptoms the patient was diagnosed with Chronic 
bronchitis/Tamakshwasa 
Criteria for assessment 
 All the signs and symptoms 
 mMRC dyspnea scale.  
 Pulmonary function test.  
 Chest x ray.  
Treatment Protocol 
A. Nebulization with Kantakari aerosol 2. 5 ml twice a day for 15 days.  
B. Oral medications: Agastyaharitaki Rasayana 5 grams twice in a day after nebulization therapy for 1 
month.  
Results 
After the whole course of treatment the condition of the patient was improved.  
Table 3: Major signs and symptoms 
S. no Signs and Symptoms BT  AT 
1 mMRC dyspnea scale 3 1 
2 Cough 1 0 
3 Wheezing 2 0 
4 Frequency of attack 2 0 
5 Chest pain 1 0 
Table 4: Pulmonary function test(PFT), Complete blood count 
S. no Test BT  AT 
1 FEV1 1. 45(l) 2. 14(l) 
2 FVC 1. 72(l) 2. 16(l) 
3 PEFR 4. 59 l/s 6. 36 l/s 
4 Hemoglobin 10. 3g/dl 11g/dl 
5 TLC 6500 /cmm 5700/cmm 
6 ESR 18 mm/hour 12 mm/hour 
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DISCUSSION
Bronchitis is the term which involves 
inflammation in the bronchi and bronchioles. It can 
be acute or chronic. Acute bronchitis occurs due to 
the viral infections in the lining of the bronchi which 
leads to accumulation of the mucus over the bronchi 
and ultimately the narrowing of the airways which 
results in the dyspnea and cough. Smoking and 
environmental pollution are the main risk factors 
responsible for the development of the chronic 
bronchitis, cigarette smoke suppose to have toxic 
particles which enters upto the level of alveoli and 
cause major destruction over there also. These toxins 
enhance inflammation over the bronchi leads to 
activation of mast cells which release macrophages 
and there is hyper secretion of mucus over there. 
These toxins in the smoke also reduce the motility or 
the cilia present in the respiratory tract, these cilia 
helps in the elimination of the excessive mucus in the 
tract, in the case of bronchitis there is decrease 
activity of the cilia which results in the accumulation 
of the mucus and obstruction of the airways. 
Nebulization is a drug delivery mode in which drug is 
administered in to the lungs in the form of mist 
through nebulizer machine. Nebulization literary 
means to convert a liquid in to a fine spray or to 
atomize or to treat with a medical spray. It is a 
method to administer the medicine via inhalation. It 
is mainly done in various respiratory disorders like 
Nasopharyngitis Asthma, Chronic Obstructive 
Pulmonary Disease (COPD), Interstitial lung diseases, 
Pneumonias. Here in this case study also herbal 
aerosol prepared through hot percolation method 
was given through nebulization. The propabable 
mode of action of inhaled drug can be understood in 
a way that after inhalation, the drug directly enters 
the lung and helps in reducing the inflammation and 
removes the mucus present over there which 
ultimately results in the relief in the symptoms. The 
drug is also supposed to have bronchodilator effects 
which results in decrease in the level of dyspnea and 
wheezing. The drug given through inhalation also 
absorbs to the systemic circulation through diffusion 
from the alveoli epithelium to the capillaries present 
in the lungs. Some part of the drugs goes to the 
gastrointestinal tract through oral cavity which 
ultimately reach the level of liver for metabolism and 
then systemic circulation. Rasayana refers to the flow 
of nutrients or more specifically to the acquisition of 
excellence of vital fluids of the body to achieve a state 
of positive health, youth and disease free living. Drug 
given in this case was Agastyaharitaki Rasayana 
which is a classical formulation prescribed for 
respiratory disorders according to Acharya charaka, 
this also acts as rejuvenating agent which helps in 
rehabilitation of the respiratory system along with 
prevention of the recurrence of the disease. 
Thisrasayan therapy overall improves the condition 
of the patient.  
CONCLUSION 
It can be concluded that Kantakari aerosol 
compound has the potential to treat the case of 
bronchitis. It can be further concluded that this 
compound can be used as therapeutic drug for the 
management of acute or chronic bronchitis. This case 
study gives a direction for searching new route of 
herbal drug administration.  
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